A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)

Abstract Background According to current evidence, the best treatment for fit patients with non-resectable pancreatic cancer (PC) is combination chemotherapy, whereas frail patients are recommended gemcitabine (Gem) monotherapy. Randomized controlled trials in colorectal cancer and a post-hoc analys...

Descripció completa

Dades bibliogràfiques

Autors principals:	Louise Skau Rasmussen, Stine B. Winther, Inna M. Chen, Britta Weber, Lise Ventzel, Gabor Liposits, Julia Sidenius Johansen, Sönke Detlefsen, Ida Egendal, Susy Shim, Signe Christensen, Per Pfeiffer, Morten Ladekarl
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2023-06-01
Col·lecció:	BMC Cancer
Matèries:	Chemotherapy dose Comorbidity Frail Older patients Pancreatic cancer Randomized study
Accés en línia:	https://doi.org/10.1186/s12885-023-11035-6
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!